PCN32 COST-MINIMISATION ANALYSIS OF ERLOTINIB VERSUS...

PCN32 COST-MINIMISATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXEDAS SECOND-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROM THE PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL

S Stefani, MG Saggia, EA Santos
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
10
Year:
2007
Language:
english
DOI:
10.1016/s1098-3015(10)65190-x
File:
PDF, 74 KB
english, 2007
Conversion to is in progress
Conversion to is failed